Gene and cell therapy developers are contending with the implications of the evolving regulatory environment while trying to progress programs as quickly as possible to address unmet needs and secure first-mover advantage in competitive indications. Regulators are facilitating efforts to truncate development timelines through a series of designations that can expedite programs while also making efforts to implement standardization.
Plasmid DNA was key to the development of biologic drug manufacturing. Today, it plays a critical role in the production of next-generation cell and gene therapies and vaccines. With its plasmid DNA manufacturing expertise, Aldevron has helped facilitate the advance of these important therapeutics. The company continues to invest in additional capacity and novel capabilities to support biopharma manufacturers into the future.
Aldevron Licenses Minicircle Technology to Support Collaboration with Myeloma Crowd and the Development of Multiple Myeloma Treatments
Aldevron to produce minicircles to support cell therapy applications
Aldevron, along with the Myeloma Crowd, a non-profit foundation dedicated to multiple myeloma patient education, advocacy and research funding, will collaborate to support research toward the advancement of treatments and a cure for multiple myeloma.